20/20 Biolabs Reports Nasdaq Bid-Price Noncompliance; Streeterville Standstill

What Happened

• 20/20 Biolabs (AIDX) disclosed that on July 17, 2026 it received a Nasdaq notice saying the company failed to meet the $1.00 closing bid-price requirement for 30 consecutive business days (June 3–July 16, 2026). Nasdaq granted a 180-calendar day compliance period through January 13, 2027 to regain compliance (ten consecutive business days with a $1.00+ closing bid).
• The company also reported a standstill agreement dated July 16, 2026 with Streeterville Capital, LLC. Streeterville previously agreed (via a November 17, 2025 securities purchase agreement) to buy up to $40,000,000 of Series E convertible preferred stock. Under the standstill, Streeterville will not seek to convert its Series E shares into common stock for 120 days unless the common stock trades at least 10% above the Nasdaq “Minimum Price” on a given trading day.

Key Details

• Series E preferred offering: up to $40,000,000 at $1,000 per preferred share (purchased under the Nov 17, 2025 agreement).
• Conversion mechanics: each Series E share has a stated value of $1,098.90 and converts at a price equal to the lower of $11.42 or 89% of the lowest 10-day VWAP prior to conversion, but not below a floor of 20% of Nasdaq’s “Minimum Price.”
• Nasdaq noncompliance window: failing the $1.00 closing bid requirement for 30 consecutive business days (June 3 to July 16, 2026); initial cure deadline is January 13, 2027 (180 days).
• Standstill term: 120 days from July 16, 2026, terminable earlier on breach or an Event of Default; the standstill is filed as Exhibit 10.1 to the 8-K.

Why It Matters

• Nasdaq notice creates a near-term compliance deadline; if the company doesn’t raise its closing bid to $1.00 for the required period (or qualify for a second compliance period and meet other listing criteria), its shares could face delisting — a material liquidity and market-access risk for investors.
• The Series E conversion terms could be dilutive if conversions occur at low prices. The standstill reduces the immediate risk of conversion-related dilution for up to 120 days by limiting Streeterville’s ability to convert, unless share prices rise substantially.
• Investors should monitor the company’s stock price, any measures management announces to regain Nasdaq compliance, and future filings about the Series E preferred, conversions, or extensions to the standstill or Nasdaq compliance period.